PERSANO, MARA
 Distribuzione geografica
Continente #
EU - Europa 10.208
NA - Nord America 443
AS - Asia 126
OC - Oceania 2
AF - Africa 1
Totale 10.780
Nazione #
IT - Italia 10.031
US - Stati Uniti d'America 435
SE - Svezia 87
CN - Cina 42
SG - Singapore 28
IN - India 24
DE - Germania 18
NL - Olanda 18
GB - Regno Unito 13
FI - Finlandia 11
FR - Francia 10
KR - Corea 8
CA - Canada 7
HK - Hong Kong 7
IE - Irlanda 4
TH - Thailandia 4
VN - Vietnam 4
BE - Belgio 3
ES - Italia 3
GR - Grecia 3
IR - Iran 3
JP - Giappone 3
AT - Austria 2
AU - Australia 2
PL - Polonia 2
IL - Israele 1
MO - Macao, regione amministrativa speciale della Cina 1
RO - Romania 1
RU - Federazione Russa 1
SC - Seychelles 1
TR - Turchia 1
TT - Trinidad e Tobago 1
UA - Ucraina 1
Totale 10.780
Città #
Cagliari 9.943
Nyköping 77
Chandler 55
Fairfield 51
Ashburn 45
Boardman 40
Houston 23
Rome 20
New York 19
Pune 19
Seattle 19
Woodbridge 18
Cambridge 17
Shanghai 17
San Diego 15
Wilmington 15
Boston 14
Amsterdam 12
Singapore 12
Helsinki 11
Seoul 8
Toronto 7
Paris 6
London 5
Menlo Park 5
Dong Ket 4
Hefei 4
Hong Kong 4
La Maddalena 4
Los Angeles 4
Naples 4
Romainville 4
Beijing 3
Jacksonville 3
Peristeri 3
San Cipriano d'Aversa 3
Sassari 3
Turin 3
Ann Arbor 2
Changzhou 2
Delhi 2
Don Mueang 2
Dublin 2
Enna 2
Gdansk 2
Godo 2
Guangzhou 2
Islington 2
Krefeld 2
Leuven 2
Livorno 2
Milan 2
Nakano 2
Nanjing 2
Norwalk 2
Olbia 2
Premià de Dalt 2
San Francisco 2
San Giorgio a Cremano 2
Sydney 2
Vienna 2
Washington 2
Xian 2
Alexandria 1
Amgaon 1
Ankara 1
Assèmini 1
Bergamo 1
Bilbao 1
Brussels 1
Chandigarh 1
Dearborn 1
Ebisu 1
Exeter 1
Frattamaggiore 1
Gela 1
Hamburg 1
Heidelberg 1
Lecce 1
Mahé 1
Miami Beach 1
Moscow 1
Naaldwijk 1
New Bedfont 1
Port-of-spain 1
Pozzuoli 1
Ravenna 1
Rockville 1
Sambuca di Sicilia 1
San Mateo 1
Shenzhen 1
Sindelfingen 1
Somerville 1
South Deerfield 1
Southwark 1
Stockholm 1
Tabriz 1
Ticusu Vechi 1
Torino 1
Zhengzhou 1
Totale 10.606
Nome #
Molecular-biology-driven treatment for metastatic colorectal cancer 2.139
New therapeutic targets in pancreatic cancer 1.312
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.255
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 615
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 481
Molecular-driven treatment for biliary tract cancer: the promising turning point 465
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 440
Uncovering key targets of success for immunotherapy in pancreatic cancer 415
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 368
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 362
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 356
BRCA-mutant pancreatic ductal adenocarcinoma 343
Immune Checkpoint Inhibitors in the Treatment of HCC 342
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 320
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 274
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 259
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 183
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 179
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 179
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 176
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 170
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 72
null 47
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 41
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 33
null 21
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index 9
Totale 10.856
Categoria #
all - tutte 17.479
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.479


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020126 0 0 0 0 0 0 55 16 12 10 8 25
2020/20212.423 32 51 33 869 469 283 94 163 63 161 109 96
2021/20221.411 84 65 4 47 57 107 68 164 112 154 244 305
2022/20233.508 301 460 353 253 266 336 167 261 246 394 310 161
2023/20243.388 145 134 122 196 301 612 613 263 195 213 353 241
Totale 10.856